Denali therapeutics announces progression and expansion of broad therapeutic portfolio for neurodegeneration and expected key milestones in 2022

South san francisco, calif., jan. 10, 2022 (globe newswire) -- denali therapeutics inc. (nasdaq: dnli), a biopharmaceutical company developing a broad portfolio of product candidates engineered to cross the blood-brain barrier (bbb) for neurodegenerative diseases, today announced program progress and expected milestones for 2022, which chief executive officer, ryan watts, ph.d., will highlight during a corporate presentation at the 40th annual j.p. morgan healthcare conference on tuesday, january 11, at 11:15 a.m. eastern time.
DNLI Ratings Summary
DNLI Quant Ranking